ClinicalTrials.gg
CompletedNCT05416229Updated Mar 24, 2026

Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

A Phase 2 interventional study of Psilocybin and Maltodextrin in Alcohol Use Disorder, sponsored by Anders Fink-Jensen, MD, DMSci. Completed at 1 site in Denmark. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Anders Fink-Jensen, MD, DMSci · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.

Enrollment
10th of 17
60 · median 62
Started
2023
with 1 other
Phase 2
16 of 17
7 open now
Registered
6th of 17
by date
Lead sponsor
2 of 17
Anders Fink-Jensen, MD, DMSci

Among the 17 studies testing psilocybin in Alcoholism, this one is the 10th largest by enrollment, is one of 2 that started in 2023, is one of 16 in phase 2, and was the 6th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing psilocybin in Alcoholism, or all of them as a file.
02

Study summary

Note: The trial is only eligible for citizens of Denmark.

The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).

Read the detailed description

To establish efficacy, we will investigate a single dose of psilocybin versus placebo in a randomised, double-blinded, placebo-controlled 12 weeks clinical trial. 90 patients, aged 20-70 years, diagnosed with alcohol use disorder and treatment seeking will be recruited from the community via advertisement and referrals from general practitioners and hospital units. The psilocybin or placebo is administered within a protocol of psychological support before, during and after the dosing. Outcome assessments will be carried out one, four, eight- and 12 weeks post dosing. The primary outcome is reduction in the percentage of heavy drinking days from baseline to follow-up at 12 weeks. Key secondary outcomes include 1) phosphatidyl-ethanol as an objective biomarker for alcohol consumption 2) plasma psilocin, the active metabolite, to establish a possible therapeutic range and 3) the acute subjective drug experience as a possible predictor of treatment outcome. Furthermore, we will investigate the neurobiological underpinnings of the possible treatment effects by use of functional magnetic resonance brain imaging one week post dosing.

03

Conditions studied

  • Alcohol Use Disorder

Keywords

  • psilocybin
  • alcohol dependence
  • addiction
  • randomized controlled trial
  • brain imaging
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bodyweight of 50-110 kg
  • AUD according to criteria and alcohol dependence according to ICD-10.
  • AUD Identification Test (AUDIT) ≥ 15.
  • ≥ 5 heavy drinking days in the past 28 days prior to inclusion.

Exclusion criteria

Exclusion Criteria:

  • Current or previously diagnosed with any psychotic disorder or bipolar affective disorder.
  • Immediate family member with a diagnosed psychotic disorder.
  • History of delirium tremens or alcohol withdrawal seizures.
  • History of suicide attempt or present suicidal ideation at screening.
  • Withdrawal symptoms at screening (>nine on the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) (43).
  • Present or former severe neurological disease including trauma with loss of consciousness > 30 min.
  • Impaired hepatic function ( >210/135 units/l men/women)
  • Cardiovascular disease defined as decompensated heart failure ( class III or IV), unstable angina pectoris, myocardial infarction within the last 12 months or uncontrolled hypertension (systolic blood pressure >165 mmHg, diastolic blood pressure >95 mmHg).
  • Present or former abnormal (>450/470 ms men/women).
  • Treatment with disulfiram, naltrexone, acamprosate and nalmefene within 28 days of inclusion.
  • Treatment with any serotonergic medication or drugs within one month prior inclusion.
  • Any oOther active substance use disorders (except nicotine) defined as a Drug Use Disorder Identification Test score >six/two (men/women) and investigator's clinical evaluation.
  • Women who are pregnant, breastfeeding, or intend to become pregnant or are not using adequate measures considered highly effective (44).
  • Unable to speak or understand Danish.
  • Any other condition that the clinician estimates can interfere with trial participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Psilocybin-assisted therapy

    45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.

    Drug: Psilocybin

  • Placebo comparator
    Placebo-assisted therapy

    45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.

    Drug: Maltodextrin

Interventions

  • Psilocybin-assisted therapy

  • DrugMaltodextrin

    Placebo-assisted therapy

06

What researchers measure

Primary outcomes

  1. Change in percentage of heavy drinking days

    Heavy drinking is defined as days with five drinks/60 grams of alcohol or more for men, four drinks/48 grams of alcohol or more for women. Data will be collected using the Timeline Followback Method (TLFB) which is a widely used, calendar-based retrospective measure of self-reported use of alcohol. The number of days drinking assessed is 28 days.

    Time frame: Baseline to week 12

Secondary outcomes

  1. Change in total alcohol consumption

    Total grams of alcohol consumed per day as measured by TLFB.

    Time frame: Baseline to week 12

  2. Change in days of abstinence

    Percentage of days without any alcohol consumption as measured by TLFB.

    Time frame: Baseline to week 12

  3. Change in phosphatidyl-ethanol (PEth)

    PEth is formed only in the presence of alcohol and is correlated with the amount of alcohol consumed the past month. PEth concentrations will be measured by peripheral blood test.

    Time frame: Baseline to week 12

  4. Change in Alcohol Use Disorders Identification Test (AUDIT)

    AUDIT is a 10-item questionnaire that measures alcohol use. The score range is 0-40, with higher scores indicating a more problematic use of alcohol.

    Time frame: Baseline to week 12

  5. Change in Penn Alcohol Craving Scale (PACS) score

    PACS is a 40-item questionnaire that measures alcohol craving severity. The score range is 0-30, with higher scores indicating more severe symptoms.

    Time frame: Baseline to week 12

  6. Change in Alcohol Abstinence Self-efficacy Scale (AASE) score

    AASE is a 40-item questionnaire that measures two scales: the temptation to drink and the confidence in the ability to avoid drinking. The score range for each scale is 0-80, with higher score indicating greater temptation or confidence, respectively.

    Time frame: Baseline to week 12

  7. Change in Fagerstrom Test for Nicotine Dependence (FTND)

    FTND is a 6-item questionnaire that measures the quantity of cigarette consumption, the compulsion to use, and dependence. The score range is 0-10, with higher scores indicating a more severe dependence.

    Time frame: Baseline to week 12

  8. Change in Drug Use Disorders Identification Test (DUDIT)

    DUDIT is an 11-item questionnaire that measures drug use. The score range is 0-44, with higher scores indication a more problematic use.

    Time frame: Baseline to week 12

  9. Change in Major Depression Inventory (MDI)

    MDI is a 12-item questionnaire that measures depression severity. The score range is 0-50, with higher scores indicating greater severity.

    Time frame: Baseline to week 12

  10. Change in Short-Form 36 (SF-36)

    SF-36 is a 36-item questionnaire that measures the quality-of-life. The score range is 0-100, with higher scores indicating better health status.

    Time frame: Baseline to week 12

  11. Change in Mindful Attention Awareness Scale (MAAS)

    MAAS is a 15-item scale that measures core characteristic of mindfulness. The score range is 1-6, with higher scores indicating greater mindfulness.

    Time frame: Baseline to week 12

  12. Change in Acceptance and Action Questionnaire (AAQ)

    AAQ is a 7-item questionnaire that measures psychological flexibility. The score range is 7-49, with higher scores indicating lesser flexibility.

    Time frame: Baseline to week 12

  13. Change in NEO-Personality Inventory (NEO-PI=

    The NEO-PI is a 240-item personality instrument that measures the five factors in the Five Factor Model. It consists of 30 eight-item facet scales, 6 for each of the five basic personality factors: Neuroticism (N), Extraversion (E), Openness (O), Agreeableness (A), and Conscientiousness (C), rated by use of a 5-point Likert-type scale ranging from strongly disagree to strongly agree.

    Time frame: Baseline to week 12

  14. Persisting Effects Questionnaire (PEQ)

    PEQ is a 143-item scale aiming to assess changes in attitudes, moods, behavior, and spiritual experience

    Time frame: Week 12

  15. Neuroplasticity and inflammation

    Neuroplasticity and inflammation as measured by mean concentrations of plasma serum brain-derived neurotrophic factor (BDNF) and plasma cytokines, respectively.

    Time frame: Baseline to week 12

  16. Subjective effects of psilocybin: Subjective Drug Intensity (SDI)

    SDI will be regularly assessed asking the patients "how intense is the experience right now" on a 0-10 Likert scale where 0 = not intense at all, 10 = very intense.

    Time frame: 0-6 hours post dosing

  17. Pharmacokinetics- and dynamics of psilocybin

    Pharmacokinetics- and dynamics of plasma psilocin, serum BDNF and plasma cytokines, as determined by concentration-time curves of mean plasma concentrations

    Time frame: 0 - 6 hours post dosing

  18. Subjective effects of psilocybin: Mystical Experience Questionnaire (MEQ)

    MEQ is a 30-item questionnaire that measures experiential aspects of psilocybin. The patients are asked to rate the items on a 6-point scale going from 0= none; not at all to 5=extreme; more than ever before in my life and stronger than 4.

    Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing

  19. Subjective effects of psilocybin: 5-Dimensional Altered State of Consciousness scale (5D-ASC)

    5D-ASC is a 94-item questionnaire that measures experiential aspects of psilocybin. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).

    Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing

  20. Subjective effects of psilocybin: Ego Dissolution Inventory (EDI)

    EDI is a 8-item questionnaire that measures the experiential aspects of psilocybin. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).

    Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing

  21. Subjective effects of psilocybin: Emotional Breakthrough Inventory (EBI)

    EBI is a 6-item questionnaire that measures the experiential aspects of psilocybin. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).

    Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing

  22. Subjective effects of psilocybin: Awe Experience Scale (AWE-S)

    AWE-S is a 30-item questionnaire that measures the experiential aspects of psilocybin. The patients are asked to rate the items on a 7-point scale going from 1= Strongly Disagree to 7= Strongly Agree.

    Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing

  23. Brain imaging

    The blood-oxygen-level-dependent differences between the two treatment arms with respect to resting-state functional connectivity, alcohol vs neutral cue-reactivity within mesocorticolimbic pathways and habitual vs goal-directed activity within corticostriatal pathways

    Time frame: 1 week post dosing

Other outcomes

  1. Role of the Music I

    We will explore the role of the music in psilocybin-assisted therapy by use of the questionnaires Experience with Music and Geneva Emotional Music Scale

    Time frame: before and after dosing

  2. Role of the Music II

    We will explore the role of the music in psilocybin-assisted therapy by qualitative semi-structured interview

    Time frame: week 4

  3. Treatment expectancies

    The Stanford Expectations of Treatment Scale is a 6 item a scale that measures positive and negative treatment expectancies using a Likert scale from 1 (strongly disagree) to 7 (strongly agree)

    Time frame: Baseline

  4. Optional long-term follow-ups

    Patients may consent to post-trial follow-up to explore the long-term effects on drinking outcomes using TLFB adjusted for current or previous treatments since completing the trial.

    Time frame: week 26 and week 52

07

Study locations

1 site
  • Psychiatric Center Copenhagen, Frederiksberg Hospital
    Frederiksberg, 2000, Denmark
08

References and documents

Publications

  • Jensen ME, Stenbaek DS, Juul TS, Fisher PM, Ekstrom CT, Knudsen GM, Fink-Jensen A. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). BMJ Open. 2022 Oct 14;12(10):e066019. doi: 10.1136/bmjopen-2022-066019. PubMed 36241352 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication. No end date.

Access criteria: Researchers who provide a methodologically sound proposal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2025, 27 months.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's 27 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 13, 2022
StartActual
Sep 1, 2023
Primary completionActual
Dec 22, 2025
CompletionActual
Dec 22, 2025
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05416229
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Collaborators
The Neurobiology Research Unit at Copenhagen University Hospital Rigshospitalet
Responsible party
Anders Fink-Jensen, MD, DMSci (Professor, Psychiatric Centre Rigshospitalet) — Sponsor-investigator
First posted
Jun 13, 2022
Start date
Sep 1, 2023
Primary completion
Dec 22, 2025
Completion
Dec 22, 2025
Last update
Mar 24, 2026

Study contacts

Anders Fink-Jensen, Professor
principal investigator · Psychiatric Center Copenhagen, Frederiksberg Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion